These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 18884684)

  • 21. Animal model for pharmacokinetic approach to individualized heparin dosage regimen for i.v. infusion by constant rate to achieve and maintain a desired clotting time.
    Ritschel WA; Brady ME
    Arzneimittelforschung; 1979; 29(12):1891-4. PubMed ID: 546429
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A simple apparatus for the determination of blood clotting-times and its application to the assay of heparin.
    BRYCE DM
    J Pharm Pharmacol; 1952 Nov; 4(11):980-4. PubMed ID: 13000674
    [No Abstract]   [Full Text] [Related]  

  • 23. Heparin administration during extracorporeal circulation: heparin rebound and postoperative bleeding.
    Kaul TK; Crow MJ; Rajah SM; Deverall PB; Watson DA
    J Thorac Cardiovasc Surg; 1979 Jul; 78(1):95-102. PubMed ID: 449391
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effect of intramuscular injections of heparin on the blood clotting time and bleeding time of chickens.
    HUMBLE RJ; GLOVER JS
    Can J Comp Med Vet Sci; 1950 Apr; 14(4):162-5. PubMed ID: 15411610
    [No Abstract]   [Full Text] [Related]  

  • 25. Relative inability of heparin to prolong clotting time of oxalated and resin-treated blood and plasma.
    SALOMON L; STEFANINI M
    Proc Soc Exp Biol Med; 1953 Nov; 84(2):476-8. PubMed ID: 13121078
    [No Abstract]   [Full Text] [Related]  

  • 26. Monitoring of intraoperative heparinization and blood loss following cardiopulmonary bypass surgery.
    Babka R; Colby C; El-Etr A; Pifarré R
    J Thorac Cardiovasc Surg; 1977 May; 73(5):780-2. PubMed ID: 850438
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Heparin neutralising activity of whole blood in patients undergoing vascular surgery.
    Harbourne T; Nicolaides AN; Golcman L; Shiffrin E
    J Cardiovasc Surg (Torino); 1987; 28(1):22-5. PubMed ID: 3805107
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The effect of heparin on three whole blood activated clotting tests and thrombin time.
    Uden DL; Seay RE; Kriesmer PJ; Cipolle RJ; Payne NR
    ASAIO Trans; 1991; 37(2):88-91. PubMed ID: 1854557
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparison of activated recalcification and partial thromboplastin tests as controls of heparin therapy.
    Ray PK; Harper TA
    J Lab Clin Med; 1971 Jun; 77(6):901-7. PubMed ID: 5559859
    [No Abstract]   [Full Text] [Related]  

  • 30. Comparison of activated coagulation time and whole blood heparin measurements with laboratory plasma anti-Xa heparin concentration in patients having cardiac operations.
    Despotis GJ; Summerfield AL; Joist JH; Goodnough LT; Santoro SA; Spitznagel E; Cox JL; Lappas DG
    J Thorac Cardiovasc Surg; 1994 Dec; 108(6):1076-82. PubMed ID: 7983877
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The effect of suboptimal concentrations of sodium citrate upon the clotting times of human and dog blood after intravenous administration of heparin.
    LOSNER S; VOLK BW
    Am J Med Sci; 1952 Dec; 224(6):673-8. PubMed ID: 12996513
    [No Abstract]   [Full Text] [Related]  

  • 32. [Coagulation parameters in high-dosage intravenous heparin therapy].
    Hafner G
    Dtsch Med Wochenschr; 1993 Aug; 118(31):1131-2. PubMed ID: 8344170
    [No Abstract]   [Full Text] [Related]  

  • 33. [Value of physiological coagulation parameters in perioperative consumption coagulopathy using low heparin doses].
    Willmen HR; Angelkort B; Müther H; Wallat U; Wenzel E
    Langenbecks Arch Chir; 1975; Suppl():423-6. PubMed ID: 1207272
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Activated partial thromboplastin time and activated coagulation time in monitoring heparinized cats.
    Greene CE; Meriwether E
    Am J Vet Res; 1982 Aug; 43(8):1473-7. PubMed ID: 7103231
    [TBL] [Abstract][Full Text] [Related]  

  • 35. In vitro and in vivo effects of hemodilution on kaolin-based activated clotting time predicted heparin requirement using a heparin dose-response technique.
    Ichikawa J; Hagihira S; Mori T; Kodaka M; Nishiyama K; Ozaki M; Komori M
    J Anesth; 2016 Dec; 30(6):923-928. PubMed ID: 27502398
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Use of activated clotting time to monitor anticoagulation during cardiac surgery.
    Niinikoski J; Laato M; Laaksonen V; Jalonen J; Inberg MV
    Scand J Thorac Cardiovasc Surg; 1984; 18(1):57-61. PubMed ID: 6609429
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Monitoring high-dose heparinization during cardiopulmonary by-pass--a comparison between prothrombinase-induced clotting time (PiCT) and two chromogenic anti-factor Xa activity assays.
    Raivio P; Kuitunen A; Petäjä J; Ilveskero S; Lassila R
    Thromb Haemost; 2008 Feb; 99(2):427-34. PubMed ID: 18278195
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Therapeutics. Guidelines for heparin administration in thromboembolic disease.
    Prupas HM
    Postgrad Med; 1977 Aug; 62(2):157-61. PubMed ID: 882468
    [No Abstract]   [Full Text] [Related]  

  • 39. [Anticoagulant treatment with heparin].
    Langer B; Wolosker M; Albers MT
    Rev Paul Med; 1982; 99(1):31-2. PubMed ID: 7146741
    [No Abstract]   [Full Text] [Related]  

  • 40. Clotting, activated partial thromboplastin and coagulation times in monitoring heparin therapy.
    Kurec AS; Morris MW; Davey FR
    Ann Clin Lab Sci; 1979; 9(6):494-500. PubMed ID: 518012
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.